Centre National De La Recherche Scientifique

Centre Hospitalier Régional Universitaire De Lille

Pascal Barbry

Bernard Mari

Brice Marcet

Monsef Benkirane

Oussama Meziane

Daniel Latreille

Robinson Triboulet

Rainer Waldmann

Jacques Reynes

Nicolas Pottier

Christelle Coraux

Christine Chable-Bessia

Yamina Bennasser

The present invention relates to the use of the miRNA expression profile, particularly of miR-199a-5p, and the target genes regulated thereby for the diagnosis, prognosis and use of miR-199a-5p inhibitors for treating fibroproliferative disorders.

Use of miR-199a-5p, targets and/or inhibitors thereof for the diagnosis, prognosis and treatment of fibroproliferative disorders

The present invention relates to at least one nucleic acid (i) comprising or consisting of or (ii) encoding a nucleic acid comprising or consisting of, a sequence selected from the group consisting of: 1) SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 4, and 2) a sequence derived from SEQ ID NO: 1 to 4 by substitution deletion or insertion of at least one nucleotide, provided that a nucleic acid consisting of the sequence derived from SEQ ID NO: 1 to 4 is liable to induce HIV-1 expression in latent HIV-1-infected cells, for use as a medicament, in particular for treating retrovirus infections.

Compositions and methods for treating retrovirus infections

The present invention relates to a method for evaluating the regenerative and/or differentiation capacity of ciliated epithelial tissue in a vertebrate subject, in particular a mammal, preferably a human, and to the use of microRNA in treating illnesses associated with a dysfunction of multiciliated epithelial cells.

Use of MicroRNA for treating diseases associated with a dysfunction of the cilia in multiciliated epithelial cells

Growing community of inventors

Nice, France

Pascal Barbry